← Back to Search

Monoclonal Antibodies

SGN-MesoC2 for Solid Tumors

Phase 1
Recruiting
Research Sponsored by Seagen Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
Participants must have histologically- or cytologically-confirmed metastatic or locally advanced unresectable ovarian cancer, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, colorectal cancer (CRC), mesothelioma, or other solid tumors, have relapsed or progressed following standard therapies, or for which no standard therapy is available.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 1 year 4 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking at a new drug called SGN-MesoC2 for treating advanced solid tumors, which are cancers that have grown in one place or spread to other parts of the body. Patients

Who is the study for?
This trial is for adults weighing at least 40 kg with certain advanced solid tumors, including ovarian cancer, NSCLC, pancreatic adenocarcinoma, colorectal cancer, and mesothelioma. Participants must have tried standard treatments without success or have no available standard options. They should be relatively active (ECOG score of 0 or 1) and have at least one measurable tumor lesion.
What is being tested?
SGN-MesoC2 is being tested in this study. It's an experimental antibody-drug conjugate designed to target and kill cancer cells while sparing normal ones. The trial has three parts: determining the right dose (Parts A & B) and assessing safety and effectiveness (Part C).
What are the potential side effects?
Potential side effects of SGN-MesoC2 may include damage to healthy cells leading to various symptoms depending on which organs are affected; however, specific side effects aren't listed here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
My cancer is advanced, cannot be surgically removed, and has not responded to standard treatments.
Select...
I can provide a sample of my tumor, either from previous tests or by a new biopsy if safe.
Select...
I weigh at least 40 kg.
Select...
My ovarian cancer is resistant to platinum-based treatments and has returned or worsened after standard treatment.
Select...
My pancreatic cancer is advanced, cannot be surgically removed, or has returned.
Select...
My cancer has worsened after standard treatments, and I've had specific chemotherapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 1 year 4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 1 year 4 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with adverse events (AEs)
Number of participants with dose modifications
Number of participants with dose-limiting toxicities (DLTs)
Secondary study objectives
Best response
Disease control rate (DCR)
Duration of response (DOR)
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SGN-MesoC2Experimental Treatment1 Intervention
SGN-MesoC2 monotherapy

Find a Location

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
210 Previous Clinical Trials
74,065 Total Patients Enrolled
~243 spots leftby Nov 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top